For oncology practices treating patients with metastatic gastrointestinal stromal tumors (GIST), balancing treatment efficacy with quality of life (QoL) is a critical priority. The phase 3 CHAPTER-GIST-301 study offers promising insights into pimitespib as a fourth-line therapy, demonstrating its ability to preserve health-related quality of life (HRQoL) while delivering clinical benefits.

This randomized, placebo-controlled trial evaluated 86 patients, focusing on HRQoL outcomes using validated tools like the EORTC QLQ-C30 and EQ-5D-5L questionnaires. The findings revealed that pimitespib, a tyrosine kinase inhibitor, maintained overall QoL for patients, with no significant deterioration compared with placebo across most metrics. However, diarrhea and appetite loss emerged as notable adverse events (AEs), occurring earlier in treatment and more frequently in the pimitespib group.

Specifically, diarrhea affected 74.1% of pimitespib-treated patients (13.8% grade ≥3), compared with only 14.3% in the placebo group. Appetite loss was reported in 31.0% of pimitespib patients, versus 7.1% in the placebo group. Despite these AEs, most diarrhea cases were reversible within a median of 33 days, and supportive care measures like antidiarrheal medications, along with dose modifications, effectively mitigated these challenges. Importantly, permanent treatment discontinuations due to AEs were rare (5.2%), highlighting the drug’s overall tolerability.

Compliance with HRQoL assessments remained high (>80%) during the initial 18 weeks of the study, reinforcing the reliability of the data. While compliance decreased after week 18, this was likely influenced by disease progression and treatment duration, common challenges in advanced cancer trials. The study’s robust design and statistical methods, including time-to-deterioration analysis, further validate the findings and underscore the importance of monitoring early AEs that might impact QoL.

For oncology teams, these insights offer actionable guidance. When prescribing pimitespib, early identification and management of AEs like diarrhea and appetite loss are crucial to preserving QoL. Additionally, integrating HRQoL data into treatment discussions can empower patients and caregivers to make informed decisions, enhancing satisfaction with care.

As practices continue to refine their approach to metastatic GIST care, the CHAPTER-GIST-301 study reinforces the importance of considering both clinical efficacy and patient experience.

Pimitespib represents a valuable addition to the therapeutic toolkit, offering hope for improved outcomes without compromising QoL, an essential consideration for patients navigating late-line therapy.

Source: Komatsu Y, Taira N, Kurokawa Y, et al. Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study. ESMO Open. 2026;11:106088.